tirzepatide versus semaglutide weight loss caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Tirzepatide Vs Semaglutide – 2026

Complex I Complex I, most commonly called NADH dehydrogenase (also known as NADH:CoQ oxidoreductase or NADH-ubiquinone oxidoreductase), is composed of NADH dehydrogenase with FMN as cofactor, plus non-heme iron proteins having at least one iron sulfur (Fe-S) center

They typically start with history, symptoms, and ruling out more common causes (sleep disorders, thyroid issues, depression/anxiety, overtraining, medication effects)

The outstanding question is long-term cardiovascular safety

Gallbladder events such as gallstones or cholecystitis occur, particularly in individuals undergoing significant or rapid weight loss over long-term use of Semaglutide

albicans viability did not differ significantly in the presence vs